Medigrowth backs National Pain Week as Gold Sponsor

Medigrowth will sponsor Chronic Pain Australia’s National Pain Week 2026 campaign from 26-31 July, backing efforts to support Australians living with chronic pain. The partnership comes as new survey data shows growing use and interest in medicinal cannabis as a pain management option.

Why it matters: - National Pain Week reaches Australians living with chronic pain at a time when demand for clearer information on treatment options remains high. - Chronic Pain Australia said the partnership with Medigrowth will help reduce stigma, elevate patient voices and improve access to reliable information. - The National Pain Survey continues to shape public understanding of chronic pain in Australia. - The latest National Pain Reports show medicinal cannabis is playing a larger role in pain management decisions.

What happened: - Medigrowth was announced as Gold Sponsor of National Pain Week 2026. - National Pain Week runs from 26 to 31 July 2026. - The campaign is Chronic Pain Australia’s flagship chronic pain awareness effort. - Medigrowth will also be Gold Sponsor of the 2026 National Pain Report. - The partnership includes a five-part video series and a longer-form interview on women’s health and pain.

The details: - The five video topics are: “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - The interview, “Pain Lives in Women’s Health,” features Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis. - The discussion covers healthcare leadership and Ellis’s endometriosis journey. - Chronic Pain Australia said the sponsorship supports its goal of pushing for pain to be recognised as a National Health Priority Area. - In the 2025 National Pain Report, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - More than half of respondents either used or were interested in medicinal cannabis as a treatment option. - Cost and driving restrictions eased slightly year on year as reported barriers. - Medigrowth describes itself as an Australian biotechnology, digital health and clinical research organisation focused on cannabinoid therapeutics and evidence-based healthcare. - Medigrowth’s work includes clinical research, cannabinoid therapeutics for the Australian market and patient support through Azure Health. - Medigrowth says its research spans women’s health, paediatric populations and chronic pain. - The company cites a randomised, double-blind, placebo-controlled trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth also cites the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organisation and the national voice for 3.6 million Australians living with chronic pain. - Chronic Pain Australia was founded in 2001 and runs National Pain Week, the National Pain Survey, PainLink support services and peer-led Pain Support Groups. - Medigrowth’s website is More information. - Chronic Pain Australia’s website is More information. - Medigrowth also shared social links for LinkedIn, Instagram and Facebook. - Chronic Pain Australia also shared social links for YouTube, TikTok, LinkedIn and X.

Between the lines: - The sponsorship positions Medigrowth inside a public health conversation that is increasingly focused on medicinal cannabis and patient education. - The survey results suggest acceptance is growing, but barriers like cost and driving rules still shape access and decision-making. - The partnership also gives Chronic Pain Australia another channel to amplify chronic pain advocacy ahead of National Pain Week.

What's next: - Chronic Pain Australia will run National Pain Week from 26 to 31 July 2026. - Medigrowth and Chronic Pain Australia are expected to use the campaign to expand education, awareness and discussion around pain management. - The 2026 National Pain Report will carry Medigrowth’s Gold Sponsor support. - The campaign is likely to keep centering patient experience and evidence-based information as part of the push for broader health recognition.